Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Advancing Platform Trials in Early Oncology by Using MATS and EXNEX in Randomized Controlled Trials.
Advancing Platform Trials in Early Oncology by Using MATS and EXNEX in Randomized Controlled Trials.
Journal: Therapeutic innovation & regulatory science
Published: October 07, 2025
A seamless phase II/III design with dose optimization for oncology drug development.
Journal: Statistics in medicine
Published: November 17, 2023
Genomic profiling and sites of metastasis in non-small cell lung cancer.
Journal: Frontiers in oncology
Published: April 26, 2023
A Multi-Arm Two-Stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials.
Journal: Contemporary clinical trials
Published: April 19, 2023
Durvalumab-induced Pure White Cell Aplasia.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: January 11, 2023
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios".
Journal: Statistics in biopharmaceutical research
Published: June 30, 2021
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 15, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 21, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 06, 2016
Last Updated: 09/26/2026